ArticleCancer immunology, immunotherapy : CII2023

Anti-PD-1 therapy in advanced sarcomas: is cutaneous primary site a stronger predictor of response than histologic subtype?

Ruoyu Miao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.